Full-day Events with Awesome Speakers
The CRISPR patent landscape beyond the United States: Europe, Asia and the rest of the world
The future of CRISPR patent licensing
Patentability issues surrounding gene-editing technologies
Common Filing Deficiencies in Abbreviated New Drug Applications (ANDA)
PARA – IV Filing & 180 days market exclusivity
Is 505(b)(2) filing a safer strategy: Avoiding a known risk?
Hatch-Waxman and BPCIA Developments
Clinical Trials, access to medicines and the regulatory provisions in India
Patient Assistance Program (PAP) and differential pricing
- Compulsory licensing, price controls, and access to patented foreign products
- Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry
- Ms. Uma Baskaran, Consultant, Krishna & Saurastri Associates LLP - Compulsory licensing, price controls and access to patented foreign products
They help us make this event possible.